Dr Charles Raison, the Director of Clinical Research at the Usona Institute and Professor in the Department of Psychiatry at the University of Wisconsin–Madison, talks to MPR about the potential of psilocybin as a therapy for major depressive disorder.

Asthma treatment gains approval for severe cases in pediatrics; Dovato gains expanded indication; Decision taken to remove ALS drug from market; Complete Response Letter issued for apomorphine device; At-home Mpox test kit made available.

First prescription smartphone app is approved for major depressive disorder; Novel blood test to detect TBI; Zevtera has been approved for bloodstream infections; The Mpox vaccine is now commercially available; Algorithm cleared for LVEF detection.

Preexposure prophylaxis approved for COVID-19; Nexletol and Nexlizet gain expanded approval; Novel Duchenne muscular dystrophy treatment; First blood test to screen for malaria in donors; Warning letter for OTC topical analgesic products.

Nasal spray approved for chronic rhinosinusitis; Endothelin receptor antagonist gains approval to lower blood pressure in hypertension; One-time stem cell treatment approved for metachromatic leukodystrophy; NASH treatment gains accelerated approval; New automated insulin delivery system for type 1 diabetes.

Weight loss treatment has approval expanded; Paxlovid with Emergency Use Authorized label must be disposed of; psychedelic gets Breakthrough therapy designation; Advisory Committee announce meeting to discuss Alzheimer treatment; ALS treatment trial results.

Over-the-counter birth control pill to be available in the coming weeks; first over-the-counter continuous glucose monitor to be available starting this summer; the 2024-2025 US influenza season vaccine will be trivalent; LSD granted Breakthrough Therapy for treatment of generalized anxiety disorder; interchangeable biosimilars to Prolia and Xgeva approved. 

FDA withdraws multiple myeloma treatment after a confirmatory trial showed an increased risk of death; latest efficacy results for Abrysvo vaccine; chikungunya virus vaccine recommendations; Complete Response Letter issued to investigative schizophrenia treatment; new treatment for complicated UTIs including pyelonephritis; over-the-counter eye ointments recalled.

First treatment approved to reduce allergic reactions in those with multiple food allergies; T-cell therapy given accelerated approval to treat unresectable or metastatic melanoma; vitamin D supplement recalled due to superpotency; cannabidiol may help resolve the symptoms of pericarditis; FDA warns against certain wearables that claim to measure blood glucose.

FDA approves first treatment for severe frostbite; Eohilia gains approval to treat eosinophilic esophagitis; MDMA accepted for Priority Review for PTSD; novel treatment to be reviewed for prurigo nodularis, atopic dermatitis; OTC pulse oximeter device is cleared.

Combination intravenous formulation of acetaminophen and ibuprofen now available; ADA recommendations for dealing with acute dental pain; RSV vaccine under review for younger age group; Gilead calls halt on investigational leukemia treatment; athlete’s foot spray recalled.

Biogen discontinues Alzheimer disease treatment; the American Academy of Dermatology issues new acne vulgaris management guidelines; update for EUA-labeled Paxlovid availability; narcolepsy/ADHD treatment recalled; FDA warns against copycat eye drop products.

T-cell malignancies prompt label changes for certain CAR T-cell immunotherapies; novel opioid provides in-built protection against overdose; hypocalcemia risk with Prolia in CKD patients; at-home intravaginal insemination kit cleared; new asthma rescue medicine approved.

Gene therapy approved for β-thalassemia; maintenance treatment for preventing of chronic inflammatory demyelinating polyneuropathy; handheld device for skin cancer detection; wearable belt device to treat low-bone mass; Narcan shelf-life extension

Researchers examine the link between diabetes, obesity treatments and suicidal ideation; topical treatment approved for molluscum contagiosum; IV bags recalled following discovery that they may contain twice as much of the labeled drug; update on penicillin shortage; newly cleared test measures HbA1c from menstrual blood.

Expert panel ranks the 30 best diets for 2024; counterfeit Ozempic identified in drug supply; a new myasthenia gravis treatment is now available; genital herpes tests may produce false positives; safety concerns over IV promethazine hydrochloride. 

Topical gel approved to treat partial thickness wounds in epidermolysis bullosa; Priority Review given to 21-valent pneumococcal conjugate vaccine; sensory and motor stimuli video game for ADHD gains expanded age approval; on-demand HIV prevention for women; multiple food allergy drug accepted for priority review.

The ADA releases updated guidance for the management of diabetes; a new blood collection device obtains lab-quality samples using a finger; novel treatment for postpartum depression becomes available; a study for a male birth control pill begins; and an application for MDMA-assisted therapy is submitted to the FDA.

Novel weight loss treatment now available in pharmacies; Novo Nordisk warns about the risks of compounded semaglutide; treatment approved for paroxysmal nocturnal hemoglobinuria; over-the-counter insemination kit cleared by the FDA.

Safety alert issued for serious reactions to certain seizure drugs; drug approved to treat a rare form of tumor; T-cell malignancies reported with cell immunotherapies; organ transplant rejection treatment recalled; CPAP machine associated with reports of burns and fires.

First chikungunya vaccine approved; FDA sends warning letter to Amazon about ophthalmic products; STI test with at-home collection cleared; Bayer withdraws lymphoma drug; and a combo treatment to reduce catheter-related bloodstream infections is approved.

New weight management treatment approved; Novo Nordisk will discontinue Levemir; renal denervation system for hypertension patients; frontotemporal dementia treatment given Fast Track designation; and the FDA advises against use of glucose supplement.

FDA urges immediate discontinuation of 26 eye drop products; safety alert issued for the pediatric Moderna COVID-19 vaccine; novel heartburn medicine approved; Stelara biosimilar approved; and a monoclonal antibody therapy to prevent fentanyl overdose gets fast tracked.

New pentavalent meningococcal vaccine approved; Gohibic’s shelf-life extended by 6 months; maintenance treatment approved for adults with moderately to severely active ulcerative colitis or Crohn disease; self-administered option for FluMist Quadrivalent accepted for review; intravenous combo formulation of acetaminophen and ibuprofen approved for postoperative pain.

FDA approves novel treatment for major depressive disorder; vote taken on stem cell therapy for ALS; preservation-free Iyuzeh now available; CDC recommends maternal RSV vaccination for infant protection; investigational treatment shows promise in familial chylomicronemia syndrome.